Please ensure Javascript is enabled for purposes of website accessibility

Tilray Launching New Medical Marijuana Brand

By Eric Volkman - Jun 8, 2021 at 3:50PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company now has three medical pot lines.

Tilray (TLRY 10.26%) is expanding its medical marijuana suite of products. The Canadian marijuana company announced Tuesday that it has rolled out a new line of medical goods in that country called Symbios. This covers a variety of formats, including flower, pre-rolled cigarettes, and oils.

The company, which was enlarged by an effective takeover by peer Canadian pot company Aphria that closed last month, is also launching a new line of high-potency medical topical products under the Aphria brand. These are intended for the treatment of inflammatory joint disease.

Users can opt for a formulation that consists of 750 milligrams of cannabidiol (CBD), or a mix of 375 milligrams each of CBD and tetrahydrocannabinol (THC).

Marijuana leaf next to a stethoscope.

Image source: Getty Images.

With the new Symbios line, Tilray now has three sets of medical cannabis goods. The third is branded under the Tilray name.

"Our industry is only in the early stages of creating and bringing to market cannabinoid medicine options that meet patient needs," the company quoted Tilray Canada president Jim Meiers as saying. "We are committed to building our leadership position in Canada now and into the future."

The medical products segment is attractive to cannabis companies because such products are typically higher-margin than recreational offerings, even though the customer base is smaller. Marijuana companies -- particularly in the relatively limited and competitive Canadian market -- are frequently unprofitable and often struggle with cash flow.

Investors seem to be guardedly optimistic about Symbios. In late-afternoon trading on Tuesday, Tilray shares were up by slightly more than 2%, outpacing the S&P 500's 0.1% gain.

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Tilray Stock Quote
Tilray
TLRY
$4.30 (10.26%) $0.40

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
377%
 
S&P 500 Returns
123%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/09/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.